All treatments
Treatment
DARZALEX 20 mg/mL concentrate for solution for infusion clinical trials
4 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations, in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and non-MSI-H Colon Cancer
This study looks at new drug combinations for advanced bowel cancer. It's for people whose cancer has grown or spread, and aims to see how well these new treatments shrink tumours, using drugs that boost the body's own immune system.
For: MSI Negative Colorectal Cancer · MSI Positive Colorectal CancerBelgium · Italy - AuthorisedTherapeutic exploratory (Phase II)
Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure - "Time is Kidney in the Treatment of myeloma Cast nephropathy" The TIKTAC phase II trial (Pilot-study)
This study looks at a new combination of medicines (DCPD) for people with multiple myeloma whose kidneys are not working well. It aims to see if kidney function improves, or if people needing dialysis can stop needing it, after four cycles of treatment.
For: Multiple myelomaAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
For: Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.Germany · Spain · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after a first-line therapy
For: multiple myelomaGermany